...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of neurology: the official journal of the European Federation of Neurological Societies >Antidiabetics, statins and the risk of amyotrophic lateral sclerosis
【24h】

Antidiabetics, statins and the risk of amyotrophic lateral sclerosis

机译：反向药，他汀类药物和肌萎缩侧面硬化症的风险

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Medications that are used for treatment of metabolic disorders have been suggested to be associated with the development of amyotrophic lateral sclerosis (ALS). Methods To examine the associations of antidiabetics and statins with the subsequent risk of ALS we conducted a population‐based nested case‐control study of 2475 Swedish residents diagnosed with ALS during July 2006 to December 2013 and 12?375 population controls (five for each ALS case). We extracted information on filled prescriptions of antidiabetics and statins for both cases and controls from the Swedish Prescribed Drug Register during the years before ALS diagnosis. Conditional logistic regression was used to calculate odds ratios (ORs) for the associations of these medications with ALS risk. Results Patients with ALS were less likely to have been prescribed with antidiabetics compared with controls [OR, 0.76; 95% confidence intervals (CI), 0.65–0.90]. Conversely, statins were not associated with ALS risk overall (OR, 1.08; 95% CI, 0.98–1.19), although a positive association was noted among women (OR, 1.28; 95% CI, 1.10–1.48). The latter association was mostly explained by ALS cases being more likely to have a first prescription of statins during the year before diagnosis compared with controls (OR, 2.54; 95% CI, 1.84–3.49). Conclusions The inverse association of antidiabetics with ALS is consistent with the previously reported inverse association between type 2 diabetes and ALS risk. The increase in prescription of statins during the year before ALS diagnosis deserves attention because it might reflect an acceleration of the course of ALS due to statin use.
机译：用于治疗代谢障碍的背景药物已经提出与肌营养的侧面硬化症（ALS）的发育相关。检查抗体和他汀类药物联想与ALS的危险风险的方法，我们在2006年7月至2013年12月和12月12日诊断为2475名瑞典居民的基于人口的嵌套病例对照研究和12？375人口控制（每个ALS为5案件）。我们提取了关于瑞典诊断前的瑞典规定药物登记液的填充抗体和他汀类药物的有关抗体处方的信息。有条件的逻辑回归用于计算这些药物与ALS风险的疗程的大量比率（或者）。结果与对照相比，患有ALS患者的患者不太可能用抗透氧剂进行规定[或0.76; 95％置信区间（CI），0.65-0.90]。相反，他汀类药物与ALS风险总体无关（或1.08; 95％CI，0.98-1.19），尽管妇女中有阳性关联（或1.28; 95％CI，1.10-1.48）。后者的关联大多是由ALS病例解释的，与对照组（或2.54; 95％CI，1.84-3.49）相比，诊断前一年中的第一个处方于他汀类药物。结论抗体与ALS的反向关联与先前报告的2型糖尿病和ALS风险的反相相关。在ALS诊断前的他汀类药物处方增加值得关注，因为它可能反映了由于他汀类药物使用的ALS过程的加速。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号